Format
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 4

1.

Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.

Reitan JF, van Breda A, Corey-Lisle PK, Shreay S, Cong Z, Legg J.

Clin Drug Investig. 2013 May;33(5):383-9. doi: 10.1007/s40261-013-0078-9.

2.

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H.

Br J Cancer. 2010 Jan 19;102(2):301-15. doi: 10.1038/sj.bjc.6605498. Epub 2010 Jan 5.

3.

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.

Grossi A, Balestri F, Santini S.

Ther Clin Risk Manag. 2007 Jun;3(2):269-75.

4.

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia.

Wauters I, Pat K, Vansteenkiste J.

Ther Clin Risk Manag. 2006 Jun;2(2):175-86.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk